Innovent Biologics Stock Performance
| IVBXF Stock | USD 4.86 0.03 0.62% |
The company retains a Market Volatility (i.e., Beta) of 0.16, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Innovent Biologics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Innovent Biologics is expected to be smaller as well. At this point, Innovent Biologics has a negative expected return of -0.14%. Please make sure to check out Innovent Biologics' variance, potential upside, as well as the relationship between the Potential Upside and day median price , to decide if Innovent Biologics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Innovent Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
| Begin Period Cash Flow | 1.3 B | |
| Total Cashflows From Investing Activities | -2.7 B |
Innovent |
Innovent Biologics Relative Risk vs. Return Landscape
If you would invest 558.00 in Innovent Biologics on September 15, 2024 and sell it today you would lose (72.00) from holding Innovent Biologics or give up 12.9% of portfolio value over 90 days. Innovent Biologics is currently producing negative expected returns and takes up 3.6058% volatility of returns over 90 trading days. Put another way, 32% of traded pink sheets are less volatile than Innovent, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Innovent Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Innovent Biologics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Innovent Biologics, and traders can use it to determine the average amount a Innovent Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0401
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IVBXF |
Estimated Market Risk
| 3.61 actual daily | 32 68% of assets are more volatile |
Expected Return
| -0.14 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Innovent Biologics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Innovent Biologics by adding Innovent Biologics to a well-diversified portfolio.
Innovent Biologics Fundamentals Growth
Innovent Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Innovent Biologics, and Innovent Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Innovent Pink Sheet performance.
| Return On Equity | -0.29 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (0.68) % | |||
| Operating Margin | (0.78) % | |||
| Current Valuation | 5.13 B | |||
| Shares Outstanding | 1.53 B | |||
| Price To Book | 4.22 X | |||
| Price To Sales | 1.39 X | |||
| Revenue | 4.27 B | |||
| EBITDA | (2.99 B) | |||
| Cash And Equivalents | 8.32 B | |||
| Cash Per Share | 5.67 X | |||
| Total Debt | 2.02 B | |||
| Debt To Equity | 0.29 % | |||
| Book Value Per Share | 6.54 X | |||
| Cash Flow From Operations | (2.02 B) | |||
| Earnings Per Share | (0.32) X | |||
| Total Asset | 16.24 B | |||
About Innovent Biologics Performance
By analyzing Innovent Biologics' fundamental ratios, stakeholders can gain valuable insights into Innovent Biologics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Innovent Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Innovent Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the Peoples Republic of China. Innovent Biologics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5538 people.Things to note about Innovent Biologics performance evaluation
Checking the ongoing alerts about Innovent Biologics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Innovent Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Innovent Biologics generated a negative expected return over the last 90 days | |
| Innovent Biologics has high historical volatility and very poor performance | |
| Innovent Biologics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 4.27 B. Net Loss for the year was (3.14 B) with profit before overhead, payroll, taxes, and interest of 2.98 B. | |
| Innovent Biologics has accumulated about 8.32 B in cash with (2.02 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from gurufocus.com: Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating ... |
- Analyzing Innovent Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Innovent Biologics' stock is overvalued or undervalued compared to its peers.
- Examining Innovent Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Innovent Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Innovent Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Innovent Biologics' pink sheet. These opinions can provide insight into Innovent Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Innovent Pink Sheet analysis
When running Innovent Biologics' price analysis, check to measure Innovent Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovent Biologics is operating at the current time. Most of Innovent Biologics' value examination focuses on studying past and present price action to predict the probability of Innovent Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovent Biologics' price. Additionally, you may evaluate how the addition of Innovent Biologics to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |